Abeona Therapeutics Inc (ABEO) is not a good buy for a beginner, long-term investor at this time. The stock shows no strong positive catalysts, has weak financial performance, and lacks significant trading signals or trends to justify an entry point. The technical indicators are neutral, and the options data suggests bearish sentiment. Additionally, there is no recent news or analyst updates to support a bullish case.

Technical Analysis

The MACD histogram is slightly positive at 0.0225, but it is contracting, indicating weakening momentum. The RSI is neutral at 49.546, and moving averages are converging, showing no clear trend. The stock is trading near its pivot level of 5.222, with resistance at 5.477 and support at 4.967. Overall, the technical indicators do not suggest a strong buy signal.

Options Data

Bullish

Open Interest Put-Call Ratio

Bearish

Option Volume Put-Call Ratio

The low Open Interest Put-Call Ratio (0.19) indicates a higher number of call options relative to puts, but the high Option Volume Put-Call Ratio (16.67) suggests significant bearish sentiment in recent trading. Implied volatility is high at 210.71, indicating uncertainty.

Technical Summary

Sell

Buy

Positive Catalysts

NULL. No recent news, insider activity, or significant trading trends to act as positive catalysts.

Neutral/Negative Catalysts

Weak financial performance in Q3 2025, with a significant drop in net income (-82.95% YoY) and EPS (-84.13% YoY). No recent news or analyst upgrades to support the stock.

Financial Performance

In Q3 2025, revenue remained at 0 with no growth. Net income dropped to -$5.16M (-82.95% YoY), and EPS declined to -0.1 (-84.13% YoY). Gross margin remained negative at -22%. The financials indicate poor performance and no signs of improvement.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No recent analyst ratings or price target updates are available for ABEO.

4 Analyst Rating

Wall Street analysts forecast ABEO stock price to rise

4 Buy

0 Hold

0 Sell

Strong Buy

Current: 5.120

Low

Averages

25.17

High

Current: 5.120

Low

Averages

25.17

High

Stifel

Stephen Willey

Buy

downgrade

$20 -> $19

AI Analysis

2025-11-12

Reason

Stifel

Stephen Willey

Price Target

$20 -> $19

AI Analysis

2025-11-12

downgrade

Buy

Reason

Stifel analyst Stephen Willey lowered the firm's price target on Abeona Therapeutics to $19 from $20 and keeps a Buy rating on the shares. Management's temporary pause on patient biopsy collection sets back the commercial launch by about three months and decreases confidence in the firm's now-lower Q4 estimate as a result of the temporal uncertainty associated with the timing of revenue recognition, the analyst tells investors in a research note. The firm added that increasing patient demand strengthens its confidence in FY26 and beyond, and believes the set-up here offers an attractive risk/reward.

Oppenheimer

Outperform

maintain

$19 -> $20

2025-08-15

Reason

Oppenheimer

Price Target

$19 -> $20

2025-08-15

maintain

Outperform

Reason

Oppenheimer raised the firm's price target on Abeona Therapeutics to $20 from $19 and keeps an Outperform rating on the shares following quarterly results and business update highlighting launch progress for Zevaskyn, after the FDA approval in April. Q2 ending cash was bolstered by the sale of Abeona's PRV during the quarter for $155M, ending Q2 with $226M.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ABEO

Unlock Now

ABEO Should I Buy

ABEO Should I Buy

Should You Buy Abeona Therapeutics Inc (ABEO) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch